Based on our previous studies that splenocytes, transduced with glutamic acid decarboxylase (GAD) 65 fused to immunoglobulin (Ig) G carrier, reduced antibody-mediated response in non-obese diabetic (NOD) mice, here we examined the mechanisms underlying Bcell tolerance in this system. We found that GAD-IgG-transduced splenocytes did not reduce CD40 expression on B cells in NOD mice, but they did downregulate CD40 ligand (CD40L) expression. Furthermore, anti-CD40L injection reduced autoantibody levels in NOD mice and in vitro experiments demonstrated that CD40L blockade reduced the antigenpresenting capability of B-cells. In conclusion, the results of this study suggest that downregulation of CD40L may be one mechanism underlying the induction of B-cell tolerance in GAD-IgGtreated NOD mice.
Introduction
Autoimmunity is a complex process that is likely to result from a summation of multiple defective tolerance mechanisms. The nonobese diabetic (NOD) mouse strain is an excellent model of autoimmune disease and important in the investigation of tolerance mechanisms. Over the past 10 years, researchers have used a wide variety of tools to study these mice.
David W. Scott and coworkers have reported the use of both heterologous and isologous immunoglobulin (Ig) G as carriers to induce tolerance. 1 -4 They engineered an immunodominant epitope in-frame at the N terminus of an IgG1 heavy chain and expressed this in bone marrow-derived cells and in lipopolysaccharide (LPS) blasts for the induction of tolerance; 2 -5 infusion of transduced cells led to potent unresponsiveness to the epitopes associated with the IgG carrier and has been used to prevent some autoimmune diseases, such as experimental autoimmune uveitis. 6 R Wang, J Wang, G Han et al.
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We have previously utilized this approach for the immunotherapy of spontaneous diabetes in NOD mice by incorporating the target antigen, glutamic acid decarboxylase (GAD) 65. We found that using the GAD-IgG fusion construct transduced splenic B-cells and induced B-cell tolerance in NOD mice. 7 It has been shown that B-cells have a crucial role as antigen-presenting cells in the pathogenic autoimmune response in NOD mice, 8 and that stimulation of CD40 in the presence of cytokines can induce profound clonal expansion and differentiation to immunoglobulin secretion and also enhance the antigen-presenting capacity of the Bcell. 9 The present study, therefore, was undertaken with the aim of investigating the mechanism underlying the induction of Bcell tolerance in NOD mice by GAD-IgG gene transfer.
Materials and methods

MICE
Female NOD mice were obtained from The Jackson Laboratory, Bar Harbor, ME, USA, and bred in our animal facilities under specific pathogen-free conditions. The study was approved by the Animal Care and Use Committee of the Institute of Basic Medical Science, Beijing, People's Republic of China.
ANTIGEN PREPARATION
The recombinant peptide GAD 500 -585 , representing the corresponding amino acids of GAD 65, was produced from Escherichia coli BL21 containing the bacterial expression vector pET28a + . The recombinant GAD 500 -585 was purified using Co 2+ -based TALON ® immobilized metal ion affinity chromatography resin (Clontech, Mountain View, CA, USA) according to the manufacturer's instructions. Eluted GAD 500 -585 fractions were dialysed against phosphatebuffered saline (PBS) (pH 7.2), filter-sterilized and verified by enzyme-linked immunosorbent assay (ELISA) and Western blot analysis (data not shown).
An unrelated his-tagged antigen (UP), also prepared and purified from E. coli BL21 in an identical manner to the recombinant GAD 500 -585 , was used as a specific control in the antibody titre and T-cell proliferation assays. Crystallized hen's egg albumin (OVA grade III; Sigma, St Louis, MO, USA) was used as the non-specific antigen.
PREPARATION OF TRANSDUCED SPLENOCYTES
Lymphocytes from donor female NOD mouse spleen were collected under sterile conditions and a suspension prepared using Ficoll ® separation liquid (GE Healthcare, Chalfont St Giles, UK). The cell suspension was washed twice with incomplete RPMI medium and then resuspended at a concentration of 5 × 10 6 cells/ml in 10% fetal calf serum (FCS; Atlanta Biologicals, Atlanta, GA, USA) using RPMI 1640 medium containing 1 mM non-essential amino acids (ICN Pharmaceuticals, Costa Mesa, CA, USA), 2 mM L-glutamine (ICN) and 50 mM 2-mercaptoethanol (ICN).
For retroviral-mediated gene transfer into LPS-stimulated and transfected splenocytes, the splenocytes (3 × 10 6 cells/ml) were then stimulated with 50 µg/ml LPS for 24 h, and cultured for another 24 h in the presence of the supernatants of GAD-IgG or IgG virusproducer cell lines together with 6 µg/ml Polybrene ® (Sigma) and 50 µg/ml LPS. Female NOD mice at 6.5 -7 weeks of age were then injected intravenously with 1 × 10 7 IgG-or GAD-IgG-transduced cells.
FLOW CYTOMETRY
Between 3 and 20 weeks after gene transfer, splenic lymphocytes were collected from NOD mice treated with IgG-or GAD-IgG-R Wang, J Wang, G Han et al.
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transduced cells and suspended in Ficoll ® separation liquid. They were resuspended in fluorescence-activated cell-sorting (FACS) buffer (PBS plus 2% FCS plus 0.05% NaN 3 ; pH 7.2) prior to flow cytometry analysis for CD40 on B-cells and CD40L on T-cells. Samples were then washed with FACS buffer and incubated with 2% anti-Fc receptor 2.4G2 diluted in FACS buffer prior to incubation with various antibodies for detection of CD40 and CD40L. Fluorescein isothiocyanate (FITC)-conjugated antimouse CD19 monoclonal antibody and phycoerythrin (PE)-conjugated anti-mouse CD40 monoclonal antibody were used for the detection of CD40 on B-cells, and FITCconjugated anti-mouse CD4 monoclonal antibody and PE-conjugated anti-mouse CD40L monoclonal antibody were used for the detection of CD40L on T-cells. All antibodies were obtained from BD Pharmingen (San Jose, CA, USA). Isotype control IgG was used as a control and, where possible, 1 × 10 6 cells were used. Cells were incubated with antibody for 30 min at 4°C, and then washed and fixed in 1% formaldehyde in saline.
Data were acquired on a FACScan ® flow cytometer (Becton Dickson, Franklin Lakes, NJ, USA) and analysed using CELLQuest ® software (Becton Dickson).
ANTI-CD40L ANTIBODY INJECTION
To investigate CD40L expression, NOD mice were injected with 50 µg/ml rat anti-murine CD40L monoclonal antibodies (BD Pharmingen) or rat control IgG (polyclonal and non-specific) (BD Pharmingen) three times per week for a total of 3 weeks. Antibody titres were measured 3 weeks after the final treatment.
ANTIBODY TITRES
Anti-GAD 500 -585 and anti-OVA antibody titres were measured in sera from mice treated with anti-murine CD40L monoclonal antibodies or control IgG using an antibody capture assay. Serial dilutions of sera from 1:40 to 1:640 were incubated with 5 µg/ml of purified his-tagged GAD 500 -585 Inc., Alexandria, VA, USA). Antibody titres were calculated as the dilution of test serum needed to reduce the signal level to threetimes that obtained with BALB/c mouse serum.
Antibody titres to an unrelated his-tagged polypeptide (UP) were also tested as a specific control.
IN VITRO STIMULATION OF T-CELLS BY B-CELLS
B-cells and CD4+ T-cells were purified from NOD mice using Dynabeads ® mouse pan B (B220) (Dynal Biotech, Carlsbad, CA, USA) and Miltenyi CD4 (L3T4) (Miltenyi Biotec, Sunnyvale, CA, USA) microbeads, respectively. The purity of B-cells and CD4+ T-cells obtained was up to 92%.
To test the ability of the B-cells to stimulate the T-cells, γ-irradiated B-cells (1.5 × 10 5 cells/well) were used to stimulate the CD4+ T-cells (2 × 10 4 cells/well) in the presence of GAD 500 -585 (30 µg/ml) or OVA Mechanisms of B-cell tolerance induction (30 µg/ml) supplemented with 50 µg/ml rat antimurine CD40L monoclonal antibodies (BD Pharmingen) or rat control IgG. On day 3, cultures were pulsed with 1 µCi/well of [ 3 H]thymidine for the last 16 h, and the cells harvested and counted by standard liquid scintillation.
The effect of an unrelated his-tagged polypeptide (UP) was also tested as a specific control.
STATISTICAL ANALYSIS
The Student's t-test was used to compare the results of each immunological experiment. A P-value < 0.05 was considered to be statistically significant.
Results
The donor and recipient female NOD mice used were aged 5 -10 and 6.5 -7 weeks, respectively. The mice used for the antibody titre and T-cell stimulation experiments were 12 weeks old. In female NOD mice, spontaneous diabetes does not appear until 12 weeks of age, increasing to 80 -90% incidence at 30 weeks of age.
CD40 EXPRESSION ON B-CELLS
Three separate experiments each using four mice per group showed that there was no change in CD40 expression on B-cells in NOD mice after GAD-IgG gene transfer (Fig.  1) : the percentages of CD40+ CD19+ cells in the IgG-and GAD-IgG-treated NOD mice were 57.62% and 55.48%, respectively (not significant).
CD40L EXPRESSION ON CD4+ T-CELLS
Expression of CD40L on T-cells was downregulated in GAD-IgG-treated NOD mice compared with IgG-treated NOD mice ( Fig. 2) : the percentages of CD40L+ CD4+ cells in the IgG-treated and GAD-IgG-treated NOD mice were 5.48% and 2.07%, respectively (P < 0.01). The data were obtained from three separate experiments each using four mice per group.
ANTIBODY RESPONSES FOLLOWING ANTI-CD40L INJECTION
The antibody responses to GAD 500 -585 reduced significantly in anti-CD40L-treated 
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NOD mice compared with the control group (P < 0.01), but there was no significant effect of anti-CD40L compared with the control following treatment with anti-OVA antibody (Fig. 3 ). This suggests that blockade of downregulation of CD40L expression results in low autoantibody levels. No antibody response (titres ≤ 10) to the UP control antigen was detected in all serum samples (data not shown). The data were obtained from three separate experiments each using four mice per group.
ANTIGEN-PRESENTING CAPABILITY OF B-CELLS
A significantly reduced CD4+ T-cell response to the antigens GAD 500 -585 and OVA was observed in splenocytes treated with anti-CD40L antibodies compared with those treated with the isotype control IgG (Fig. 4 ). 
Discussion
We have previously shown that transfer of GAD-IgG-transduced splenocytes produced a reduced humoral response in NOD mice. 7 In the present study GAD-IgG gene transfer was seen to downregulate CD40L expression ( Fig.  2) but did not reduce CD40 expression ( Fig.  1) in NOD mice. Development of the acquired immune response is dependent on the stimulation of CD40 signalling by its ligand CD40L. These molecules govern both the magnitude and the quality of humoraland cell-mediated immunity. 9 High CD40L expression correlates with diseases such as systemic lupus erythematosus, peritonitis, acute anterior uveitis, acute and chronic heart failure, angiographic restenosis, colitis, liver ischaemia and reperfusion inflammatory responses. 10 -16 Considerable effort by clinicians and scientists has focused on the utility of new biomarkers such as CD40L to prevent, diagnose and manage adverse inflammatory responses. 17 A number of studies have conclusively documented that blockade of the CD40L-CD40 ligand-receptor pair can prevent and intervene in the progression of antibody-and cell-mediated autoimmune diseases, and is also associated with longlived allogeneic and xenogeneic graft tolerance. 10 -17 The results of the present study suggest that downregulation of CD40L expression, as induced by GAD-IgG gene transfer, may have an important role in Bcell tolerance and may, therefore, have implications for the treatment of diabetes.
We then investigated further the association of downregulated CD40L expression and B-cell tolerance seen in GAD-IgG-treated NOD mice. The pivotal role played by CD40 in governing humoral and cell-mediated immunity is manifested by the capacity of the CD40L-CD40 pair to activate B-cells; engagement of CD40 in the 
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presence of cytokines can induce differentiation and Ig secretion. 9 Reduced anti-GAD 500 -585 antibody titres were seen in the serum of mice injected with anti-CD40L, suggesting that downregulation of CD40L expression made CD40 signalling inadequate, resulting in low GAD-specific antibody production ( Fig. 3 ).
It has previously been shown that B-cells are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD 65 antigen in NOD mice. 18 B-cells can prime naive CD4+ T-cells in vivo in the absence of other antigen-presenting cells in a CD40L-CD40-dependent manner. 19 In addition to being important to B-cell clonal expansion, germinal centre formation, isotype switching, affinity maturation and the generation of long-lived plasma cells, 18 the CD40L-CD40 co-stimulatory pathway also enhances the antigen-presenting cell capacity of B-cells. 9 CD40L-CD40 interaction provides a bidirectional signal for T-and B-cell activation. The results of the present study suggest that anti-CD40L antibodies can reduce the capacity of B-cells to present antigens ( Fig. 4 ). Possible mechanisms of tolerance induction by CD40L-CD40 blockade include a reduction in the expression of B7 molecules, effects on the bcl-xL gene or antigen-presenting cell function modification. 20 Blockade of the CD40-CD40L ligand-receptor pair has a number of uses. For example, it is effective in abrogating autoimmune diseases 21 and inducing transplantation tolerance. 22, 23 Many autoimmune models of disease in mice have been shown to be blocked by treatment with αCD40L, including experimental autoimmune encephalomyelitis, diabetes, collagen-induced arthritis, uveitis, thyroiditis and lupus. 24 -29 In addition to controlling autoimmune diseases, the prevention of transplant rejection by blocking CD40-CD40L interactions has been repeatedly reported in the induction of long-term tolerance to skin, 23,30 -33 islet, 34 bone marrow 35 and a myriad of other transplanted organs. 36, 37 Early studies by Qin et al. 38 were the first to describe an infectious form of tolerance in a variety of allograft tolerance systems.
In conclusion, the present study, in conjunction with what has also been found in other studies, demonstrated that GAD-IgG gene transfer downregulated CD40L expression and that CD40L blockade may result in B-cell tolerance. These results suggest that a reduction in CD40L expression may be one mechanism underlying the induction of B-cell tolerance in GAD-IgG-treated NOD mice.
